Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Deirdre Mladsi,1 Christine Barnett,1 Kavita Aggarwal,2 Michael Vredenburg,2 Douglas Dieterich,3 Ray Kim4 1RTI Health Solutions Research, Triangle Park, NC, USA; 2Dova Pharmaceuticals, Durham, NC, USA; 3Icahn School of Medicine, New York, NY, USA; 4School of Medicine, Stanford University, Stanford, C...
Saved in:
Main Authors: | Mladsi D (Author), Barnett C (Author), Aggarwal K (Author), Vredenburg M (Author), Dieterich D (Author), Kim R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
by: Yong-Shuai Wang, et al.
Published: (2022) -
Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
by: Tsykunova G, et al.
Published: (2022) -
Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
by: Andrea Aiello, et al.
Published: (2023) -
Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study
by: Yongsheng Ruan, et al.
Published: (2023) -
Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia
by: Xiaofang Tu, et al.
Published: (2022)